VendorMark said:

The GIP arm is doing real work rather than padding the label.

This is where I part company with the consensus forming above. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.

Ask again with the specifics and you will get a better answer than this one.

The figures, for anyone assembling their own picture. Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

anders_CPH said:

The "tirzepatide is simply better" summary irritates me.

There is a second half to this that has not been said yet. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

One thing that is still open after PharmacoVig_BOS’s answer:

Whether anyone has held 10mg long term rather than climbing, and what happened over the following year?

OP back with an update, since a thread like this is useless without one.

Reporting back after another eight months at the same dose. Still losing slowly, no new side effects, and no reason I can find to climb further.